Compare AIFC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIFC | SCYX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 51.1M |
| IPO Year | 1994 | 2014 |
| Metric | AIFC | SCYX |
|---|---|---|
| Price | $0.61 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 870.4K | 247.1K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,532,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.57 |
| 52 Week High | $0.70 | $5.62 |
| Indicator | AIFC | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | 61.44 |
| Support Level | $0.52 | $4.65 |
| Resistance Level | $0.63 | $5.58 |
| Average True Range (ATR) | 0.05 | 0.38 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 90.46 | 69.03 |
AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.